OZURDEX® has been shown to reduce DME through anti-inflammatory effects, vascular effects and by activating draining mechanisms*1-6
*Supporting evidence includes data from animal models.
Images owned by AbbVie.
Abbreviations and references
DME, diabetic macular edema; ICAM-1, intercellular adhesion molecule 1; IL-1β, interleukin 1 beta; IL-6, interleukin 6; MCP-1, monocyte chemoattractant protein 1; TNF-α, tumour necrosis factor alfa; VEGF, vascular endothelial growth factor.
1. OZURDEX® SPC.
2. Nehme A and Edelman J. Invest Ophthalmol Vis Sci 2008; 49(5): 2030-8.
3. Garcia-Layana A et al. Ophthalmologica 2018; 240(2): 61-72.
4. Siqueiros-Marquez L et al. Invest Ophthalmol Vis Sci 2017; 58(2): 876-86.
5. Wang K et al. Biol Pharm Bull 2008; 31(8): 1541-6.
6. Zhao M et al. Invest Ophthalmol Vis Sci 2011; 52(9): 6340-7.
Job Number ALL-OZU-220048. Date of Preparation March 2023
OZURDEX® (dexamethasone intravitreal implant) is indicated for the treatment of adult patients with:
- Visual impairment due to diabetic macular edema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy
- Macular edema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
- Inflammation of the posterior segment of the eye presenting as non-infectious uveitis
Adverse events should be reported. Reporting forms and information can be found at XXXX
Adverse events should also be reported to AbbVie on GVPV@abbvie.com
Our therapy areas
Additional info
Report Adverse Event (AE reporting requirements to be localized)
This website is for Healthcare Professionals only
Job Number ALL-OZU-220048. Date of Preparation March 2023. This website has been developed and funded by AbbVie Ltd.
© 2019 AbbVie Ltd. All rights reserved. Registered number: 08004972 England.